XOMA Ltd. (
Lazard Capital Markets Healthcare Conference 2011
November 15, 2011 1 AM ET
John Varian – Interim CEO
Paul Rubin – VP, Clinical Development and Chief Medical Officer
[Starts Abruptly] introduce John Varian, who will be presenting to us today about his company XOMA.
Thanks Colleen, and thank you to Lazard for having us present here giving us the opportunity to talk about XOMA and some of the new changes that are going on there. I joined the company at the end of August as the interim CEO. I've been involved with XOMA for the last nearly almost 3 years as a board member, and during those 3 years our focus has been on really one thing. XOMA is a company that over the years has had terrific science but there is a belief among the board and I think many others that XOMA has not really benefited as much from its own discoveries as it should have and so our focus has been on changing that making sure we are in a position to benefit from our own discoveries.
We’ll be making forward-looking statements of course today. So if you look at the assets that we have at XOMA the primary asset the thing that most people are focused on is XOMA 052 and it has just received its official name which is gevokizumab. So gevokizumab, it will be 052 we’ll be saying it that way today. Gevokizumab targets IL-1 beta, which is a validated anti-inflammatory target. We will be talking primarily today about an announcement which we made last week, which is a combination of really two things that we are implementing to build more value around gevokizumab.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts